First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice

Scherließ, Regina; Mönckedieck, Mathias; Young, Katherine; Trows, Sabrina; Buske, Simon; Hook, Sarah

doi:10.1016/j.ijpharm.2015.01.015

Cited by 23 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For comparison, agarose nanoparticles were produced by nanoprecipitation. Both particulate vaccine systems have been assessed in a mouse model after nasal dry-powder administration and without the use of further adjuvants created higher local cellular immune responses than ovalbumin alone [119].…”

Section: Respiratory Vaccine Formulationsmentioning

confidence: 99%

Mucosal Vaccination via the Respiratory Tract

Hellfritzsch

Scherließ

2019

Pharmaceutics

View full text Add to dashboard Cite

Vaccine delivery via mucosal surfaces is an interesting alternative to parenteral vaccine administration, as it avoids the use of a needle and syringe. Mucosal vaccine administration also targets the mucosal immune system, which is the largest lymphoid tissue in the human body. The mucosal immune response involves systemic, antigen-specific humoral and cellular immune response in addition to a local response which is characterised by a predominantly cytotoxic T cell response in combination with secreted IgA. This antibody facilitates pathogen recognition and deletion prior to entrance into the body. Hence, administration via the respiratory mucosa can be favoured for all pathogens which use the respiratory tract as entry to the body, such as influenza and for all diseases directly affecting the respiratory tract such as pneumonia. Additionally, the different mucosal tissues of the human body are interconnected via the so-called “common mucosal immune system”, which allows induction of an antigen-specific immune response in distant mucosal sites. Finally, mucosal administration is also interesting in the area of therapeutic vaccination, in which a predominant cellular immune response is required, as this can efficiently be induced by this route of delivery. The review gives an introduction to respiratory vaccination, formulation approaches and application strategies.

show abstract

Section: Respiratory Vaccine Formulationsmentioning

confidence: 99%

Mucosal Vaccination via the Respiratory Tract

Hellfritzsch

Scherließ

2019

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Accordingly, the nose can be a great alternative administration route in the therapy of CNS diseases or when the target is in the CNS (e.g., brain tumors). Thus, in recent years, researchers have made some efforts to formulate drug delivery systems for the treatment of schizophrenia [11,12], epilepsy [13,14], Alzheimer's disease [15][16][17][18], Parkinson's disease [19,20], migraine [21], vaccination [22,23], and brain tumor [24]. In some cases the aim was to formulate nanosystems, that may be advantageous due to reduced particle size and increased particle surface, which can affect the absorption positively [25].…”

Section: Introductionmentioning

confidence: 99%

Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity

et al. 2020

View full text Add to dashboard Cite

Nasal drug delivery has become a popular research field in the last years. This is not surprising since the nose possesses unique anatomical and physical properties. Via the nasal mucosa local, systemic, and directly central nerve systemic (CNS) effect is achievable. Powders have favorable physicochemical properties over liquid formulations. Lamotrigine (LAM) is an antiepileptic agent with a relatively mild side effect spectrum, but only available in tablet form on market. Reducing the particle size to the nano range can affect the bioavailability of pharmaceutical products. The aim of this article was to continue the work started, compare the in vitro properties of a nanonized lamotrigine containing nasal powder (nanoLAMpowder) and its physical mixture (PM) that were prepared by dry milling. Moreover, to study their trans-epithelial absorption to reach the blood and target the brain by axonal transport. Due to the dry milling technique, the particle size of LAM, their surface and also their structure changed that led to higher in vitro dissolution and permeability rate. The results of the in vivo tests showed that the axonal transport of the drug was assumable by both intranasal formulations because the drug was present in the brain within a really short time, but the LAM from the nanoLAMpowder liberated even faster.

show abstract

“…As a result, preservatives are not needed and also the unexpected incompatibilities are not common. Their shelf life is longer and the transport is much easier, but packaging must ensure protection against humidity and light [8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%